Spinal central effects of peripherally applied botulinum neurotoxin A in comparison between its subtypes A1 and A2

Frontiers in Neurology

Volumn 5 JUN, Issue , 2014, Pages

  Koizumi, Hidetaka ^a   Goto, Satoshi ^a   Okita, Shinya ^a   Morigaki, Ryoma ^a   Akaike, Norio ^b   Torii, Yasushi ^c,d   Harakawa, Tetsuhiro ^c   Ginnaga, Akihiro ^c   Kaji, Ryuji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KUMAMOTO HEALTH SCIENCE UNIVERSITY   (Japan)

^c Kaketsuken   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Axonal transport; Botulinum neurotoxin; Central effects; SNAP 25; Spinal cord

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN A1; BOTULINUM TOXIN A2; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; COMPOUND MUSCLE ACTION POTENTIAL; CONTROLLED STUDY; DOSE RESPONSE; GASTROCNEMIUS MUSCLE; HINDLIMB; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MUSCLE ACTION POTENTIAL; MUSCLE FLACCIDITY; MUSCLE WEAKNESS; NERVE FIBER TRANSPORT; NONHUMAN; PROTEIN CLEAVAGE; RAT; SPINAL CORD DORSAL HORN; SPINAL CORD VENTRAL HORN; TRANSCYTOSIS;

EID: 84904428912     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2014.00098     Document Type: Article

References (37)

1. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci (2002) 27:552-8. doi: 10.1016/S0968-0004(02)02177-1
2. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis (2014) 209:183-91. doi:10.1093/infdis/jit449
3. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA (2011) 305:89-90. doi:10.1001/jama.2010.1937
4. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord (2013) 28:1775-83. doi:10.1002/mds.25582
5. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: botulinum neurotoxin in the treatment of spasticity (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology (2008) 70:1691-8. doi:10.1212/01.wnl.0000311391.00944.c4
6. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: botulinum neurotoxin in the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology (2008) 70:1699-706. doi:10.1212/01.wnl.0000311389.26145.95
7. Naumann M, So Y, ArgoffCE, Childers MK, Dykstra DD, Gronseth GS, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology (2008) 70:1707-14. doi:10.1212/01.wnl.0000311390.87642.d8
8. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev (2000) 80:717-66.
9. Dolly JO, Lawrence GW, Meng J, Wang J, Ovsepian SV. Neuro-excytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr Opin Pharmacol (2009) 9:326-35. doi:10.1016/j.coph.2009.03.004
10. Restani L, Novelli E, Bottari D, Leone P, Barone I, Galli-Resta L, et al. Botulinum neurotoxin A impairs neurotransmission following retrograde transsynaptic transport. Traffic (2012) 13:1083-9. doi:10.1111/j.1600-0854.2012.01369.x
11. Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, et al. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 362:733-42. doi:10.1016/j.jmb.2006.07.040
12. Dover N, Barash JR, Arnon SS. Novel Clostridium botulinum toxin gene arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes. J Clin Microbiol (2009) 47:2349-50. doi:10.1128/JCM.00799-09
13. Whitemarsh RC, Tepp WH, Bradshaw M, Lin G, Pier CL, Scherf JM, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun (2013) 81:3894-902. doi:10.1128/IAI.00536-13
14. Caleo M, Antonucci F, Restani L, Mazzochio R. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem (2009) 109:15-24. doi:10.1111/j.1471-4159.2009.05887.x
15. Kaji R. Direct central action of intramuscularly injected botulinum toxin: is it harmful or beneficial? J Physiol (2013) 591(Pt 4):749. doi:10.1113/jphysiol.2012.246322
16. Sakaguchi G, Ohishi I, Kozaki S. Purification and oral toxicities of Clostridium botulinum progenitor toxins. In: Lewis GE, editor. Biomedical Aspects of Botulism. New York, NY: Academic Press (1981). p. 21-34.
17. Torii Y, Akaike N, Harakawa T, Kato K, Sugimoto N, Goto Y, et al. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats. J Pharmacol Sci (2011) 117:275-85. doi:10.1254/jphs.11121FP
18. Sakamoto T, Torii Y, Takahashi M, Ishida S, Goto Y, Nakano H, et al. Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats. Toxicon (2009) 54:857-61. doi:10.1016/j.toxicon.2009.06.020
19. Yamamura Y, Morigaki R, Kasahara J, Yokoyama H, Tanabe A, Okita S, et al. Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice. Front Cell Neurosci (2013) 7:12. doi:10.3389/fncel.2013.00012
20. Goto S, Kawarai T, Morigaki R, Okita S, Koizumi H, Nagahiro S, et al. Defects in the striatal neuropeptide Y system in X-linked dystonia-parkinsonism. Brain (2013) 136(Pt 5):1555-67. doi:10.1093/brain/awt084
21. Koizumi H, Morigaki R, Okita S, Nagahiro S, Kaji R, Nakagawa M, et al. Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role. Front Cell Neurosci (2013) 7:74. doi:10.3389/fncel.2013.00074
22. Hallis B, James BA, Shone CC. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J Clin Microbiol (1996) 34:1934-8.
23. Panneton WM, Gan Q, Juric R. The central termination of sensory fibers from nerves to the gastrocnemius muscle of the rat. Neuroscience (2005) 134:175-87. doi:10.1016/j.neuroscience.2005.02.032
24. Akaike N, Shin MC, Wakita M, Torii Y, Harakawa T, Ginnaga A, et al. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol (2013) 591:1031-43. doi:10.1113/jphysiol.2012.242131
25. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci (2008) 28:3689-96. doi:10.1523/JNEUROSCI.0375-08.2008
26. Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci (2011) 31:15650-9. doi:10.1523/JNEUROSCI.2618-11.2011
27. Matak I, Riederer P, Lackovic Z. Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem Int (2012) 61:236-9. doi:10.1016/j.neuint.2012.05.001
28. Marchand-Pauvert V, Aymard C, Giboin LS, Dominici F, Rossi A, Mazzocchio R. Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol (2013) 591:1017-29. doi:10.1113/jphysiol.2012.239178
29. Caleo M, Schiavo G. Central effects of tetanus and botulinum neurotoxins. Toxicon (2009) 54:593-9. doi:10.1016/j.toxicon.2008.12.026
30. Moreno-López B, Pastor AM, de la Cruz RR, Delgado-García JM. Dose-dependent, central effects of botulinum neurotoxin type A: a pilot study in the alert behaving cat. Neurology (1997) 48:456-64. doi:10.1212/WNL.48.2.456
31. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord (2011) 17:S28-33. doi:10.1016/j.parkreldis.2011.06.013
32. Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience (2011) 186:201-7. doi:10.1016/j.neuroscience.2011.04.026
33. Filipovic B, Matak I, Bach-Rojecky L, Lackovic Z. Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One (2012) 7:e29803. doi:10.1371/journal.pone.0029803
34. Favre-Guilmard C, Auguet M, Chabrier PE. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol (2009) 617:48-53. doi:10.1016/j.ejphar.2009.06.047
35. Bach-Rojecky L, Salkovic-Petrisic M, Lackovic Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol (2010) 633:10-4. doi:10.1016/j.ejphar.2010.01.020
36. Ritz LA, Murray CR, Foli K. Crossed and uncrossed projections to the cat sacrocaudal spinal cord: III. Axons expressing calcitonin gene-related peptide immunoreactivity. J Comp Neurol (2002) 438:388-98. doi:10.1002/cne.1322
37. Akaike N, Ito Y, Shin MC, Nonaka K, Torii Y, Harakawa T, et al. Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses. Toxicon (2010) 56:1315-26. doi:10.1016/j.toxicon.2010.07.015